Payment overview · 2025
General Payments
$630.29
33 reported records · 10 companies
Healthcare provider profile · identity verified
Michael P Riggleman, MD
Allopathic & Osteopathic Physicians|Family Medicine · MOOREFIELD, WV · NPI 1831163500
Verified facts
What the public records show
CMS Open Payments records show Michael P Riggleman, MD received $630.29 in general payments during 2025 across 33 reported records.
AstraZeneca Pharmaceuticals LP accounted for 22.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Ozempic, Rybelsus, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 424 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $144.33 | 22.9% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $142.19 | 22.6% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $117.72 | 18.7% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $49.53 | 7.9% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $44.21 | 7.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $43.83 | 7.0% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $42.87 | 6.8% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.00 | 2.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $14.40 | 2.3% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $14.21 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $630.29 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $142.19 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $142.19 | 8 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $117.72 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $117.72 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $115.38 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $92.13 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $49.53 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $44.21 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $43.83 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $43.83 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $42.87 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $14.40 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $14.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 424 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 56 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 87 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
56 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
87 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
424 | 55 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
26 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1027 | 121 |
| Furosemide | Furosemide | 975 | 130 |
| Atorvastatin Calcium | Atorvastatin Calcium | 802 | 180 |
| Potassium Chloride | Potassium Chloride | 797 | 86 |
| Pantoprazole Sodium | Pantoprazole Sodium | 739 | 102 |
| Omeprazole | Omeprazole | 702 | 140 |
| Gabapentin | Gabapentin | 566 | 86 |
| Metoprolol Tartrate | Metoprolol Tartrate | 541 | 86 |
| Amlodipine Besylate | Amlodipine Besylate | 534 | 118 |
| Metformin Hcl | Metformin Hcl | 514 | 98 |
| Lisinopril | Lisinopril | 513 | 108 |
| Metoprolol Succinate | Metoprolol Succinate | 493 | 79 |
| Tramadol Hcl | Tramadol Hcl | 445 | 69 |
| Eliquis | Apixaban | 424 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 362 | 61 |
| Losartan Potassium | Losartan Potassium | 337 | 64 |
| Lorazepam | Lorazepam | 336 | 44 |
| Escitalopram Oxalate | Escitalopram Oxalate | 324 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 318 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 287 | 55 |
| Sertraline Hcl | Sertraline Hcl | 278 | 42 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 255 | 33 |
| Diclofenac Sodium | Diclofenac Sodium | 234 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 229 | 46 |
| Famotidine | Famotidine | 211 | 28 |
| Carvedilol | Carvedilol | 207 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 203 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 202 | 12 |
| Simvastatin | Simvastatin | 194 | 41 |
| Prednisone | Prednisone | 190 | 80 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 188 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 183 | 64 |
| Glipizide Er | Glipizide | 183 | 42 |
| Trazodone Hcl | Trazodone Hcl | 180 | 39 |
| Citalopram Hbr | Citalopram Hydrobromide | 177 | 33 |
| Hydralazine Hcl | Hydralazine Hcl | 174 | 16 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 173 | 14 |
| Glipizide | Glipizide | 171 | 31 |
| Donepezil Hcl | Donepezil Hcl | 169 | 16 |
| Buspirone Hcl | Buspirone Hcl | 168 | 21 |
| Mirtazapine | Mirtazapine | 156 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 154 | 38 |
| Olanzapine | Olanzapine | 152 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 147 | 41 |
| Allopurinol | Allopurinol | 140 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 140 | 21 |
| Montelukast Sodium | Montelukast Sodium | 137 | 30 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 137 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 134 | 20 |
| Divalproex Sodium | Divalproex Sodium | 132 | 11 |
| Memantine Hcl | Memantine Hcl | 127 | 13 |
| Alprazolam | Alprazolam | 125 | 25 |
| Risperidone | Risperidone | 123 | suppressed |
| Atenolol | Atenolol | 117 | 26 |
| Sucralfate | Sucralfate | 115 | 11 |
| Celecoxib | Celecoxib | 114 | 24 |
| Spironolactone | Spironolactone | 114 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 113 | 46 |
| Levetiracetam | Levetiracetam | 109 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 107 | suppressed |
| Naproxen | Naproxen | 98 | 28 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 95 | 13 |
| Warfarin Sodium | Warfarin Sodium | 91 | 12 |
| Meloxicam | Meloxicam | 90 | 25 |
| Baclofen | Baclofen | 89 | 14 |
| Nifedipine Er | Nifedipine | 89 | suppressed |
| Ozempic | Semaglutide | 87 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 85 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 84 | 11 |
| Xarelto | Rivaroxaban | 83 | 15 |
| Cefdinir | Cefdinir | 82 | 59 |
| Lovastatin | Lovastatin | 82 | 17 |
| Ezetimibe | Ezetimibe | 79 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 79 | 15 |
| Tresiba Flextouch U-100 | Insulin Degludec | 79 | 14 |
| Ibuprofen | Ibuprofen | 77 | 29 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 74 | 69 |
| Januvia | Sitagliptin Phosphate | 74 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 74 | 29 |
| Cephalexin | Cephalexin | 73 | 36 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 73 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 71 | 21 |
| Jardiance | Empagliflozin | 70 | 18 |
| Glimepiride | Glimepiride | 69 | 11 |
| Azithromycin | Azithromycin | 68 | 49 |
| Clonazepam | Clonazepam | 68 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 68 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 63 | 45 |
| Metoclopramide Hcl | Metoclopramide Hcl | 61 | 14 |
| Pregabalin | Pregabalin | 61 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 59 | 38 |
| Fenofibrate | Fenofibrate | 58 | 16 |
| Farxiga | Dapagliflozin Propanediol | 56 | 14 |
| Novolog Flexpen | Insulin Aspart | 56 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 56 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 55 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 53 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 53 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | suppressed |
| Digoxin | Digoxin | 50 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 50 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 50 | suppressed |
| Rivastigmine | Rivastigmine | 50 | suppressed |
| Fluconazole | Fluconazole | 48 | 20 |
| Acyclovir | Acyclovir | 47 | suppressed |
| Mounjaro | Tirzepatide | 46 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 45 | suppressed |
| Carbamazepine | Carbamazepine | 44 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 43 | suppressed |
| Rybelsus | Semaglutide | 43 | suppressed |
| Acarbose | Acarbose | 42 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 41 | 11 |
| Admelog Solostar | Insulin Lispro | 41 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 27 |
| Alendronate Sodium | Alendronate Sodium | 40 | suppressed |
| Amoxicillin | Amoxicillin | 39 | 33 |
| Tradjenta | Linagliptin | 38 | suppressed |
| Haloperidol | Haloperidol | 37 | suppressed |
| Aripiprazole | Aripiprazole | 36 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 36 | suppressed |
| Ketoconazole | Ketoconazole | 36 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | suppressed |
| Methocarbamol | Methocarbamol | 36 | 11 |
| Torsemide | Torsemide | 36 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 35 | 20 |
| Nystatin | Nystatin | 35 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Trulicity | Dulaglutide | 33 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 23 |
| Propranolol Hcl Er | Propranolol Hcl | 30 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 30 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 30 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Methimazole | Methimazole | 29 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 28 | 14 |
| Morphine Sulfate | Morphine Sulfate | 28 | 25 |
| Finasteride | Finasteride | 27 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 27 | 19 |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Dutasteride | Dutasteride | 26 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 26 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 26 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 26 |
| Prazosin Hcl | Prazosin Hcl | 26 | suppressed |
| Ranolazine Er | Ranolazine | 25 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 24 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 24 | suppressed |
| Latanoprost | Latanoprost | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 15 |
| Valproic Acid | Valproic Acid | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | suppressed |
| Fentanyl | Fentanyl | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 20 | suppressed |
| Methotrexate | Methotrexate Sodium | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 17 |
| Primidone | Primidone | 20 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 19 | suppressed |
| Carbamazepine Er | Carbamazepine | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 18 | 18 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Buprenorphine | Buprenorphine | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Ibu | Ibuprofen | 15 | suppressed |
| Travoprost | Travoprost | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Sulindac | Sulindac | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | suppressed |
| Lorazepam Intensol | Lorazepam | 13 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Nyamyc | Nystatin | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Lumigan | Bimatoprost | 11 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $630.29 · 33 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, CAPLYTA, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, JOURNAVX, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Rybelsus, The Cologuard Plus Collection Kit, VOQUEZNA, VRAYLAR | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error